PDF(Pubmed)
Abstract：
Cymbopogon citratus (DC) stapf. (Gramineae) is a herb known worldwide as lemongrass. The oil obtained, i.e., lemongrass oil has emerged as one among the most relevant natural oils in the pharmaceutical industry owing to its extensive pharmacological and therapeutic benefits including antioxidant, antimicrobial, antiviral and anticancer properties. However, its usage in novel formulations is constrained because of its instability and volatility. To address these concerns, the present study aims to formulate lemongrass-loaded SLN (LGSLN) using hot water titration technique. In the Smix, Tween 80 was selected as a surfactant component, while ethanol was taken as a co-surfactant. Different ratios of Smix (1:1, 1:2, 1:3, 2:1 and 3:1) were utilized to formulate LG-loaded SLN. The results indicated the fact that the LGSLN formulation (abbreviated as LGSLN1), containing lipid phase 10% w/w (i.e., LG 3.33% and SA 6.67%), Tween 80 (20% w/w), ethanol (20% w/w) and distilled water (50% w/w), revealed suitable nanometric size (142.3 ± 5.96 nm) with a high zeta potential value (- 29.12 ± 1.7 mV) and a high entrapment efficiency (77.02 ± 8.12%). A rapid drug release (71.65 ± 5.33%) was observed for LGSLN1 in a time span of 24 h. Additionally, the highest values for steady-state flux (Jss; 0.6133 ± 0.0361 mg/cm2/h), permeability coefficient (Kp; 0.4573 ± 0.0141 (cm/h) × 102) and enhancement ratio (Er; 13.50) was also conferred by LGSLN1. Based on in vitro study results, the developed SLN appeared as a potential carrier for enhanced topical administration of lemongrass oil. The observed results also indicated the fact that the phyto-cosmeceutical prospective of the nanolipidic carrier for topical administration of lemongrass oil utilizing pharmaceutically acceptable components can be explored further for widespread clinical applicability.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s13205-023-03726-5.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s13205-023-03726-5.
摘要：
Cymboponcitratratus(DC)stapf.（禾本科）是一种在世界范围内被称为柠檬草的草本植物。获得的油，即，柠檬草油已成为制药工业中最相关的天然油之一，由于其广泛的药理和治疗益处，包括抗氧化剂，抗菌，抗病毒和抗癌特性。然而,由于其不稳定性和挥发性，其在新型配方中的使用受到限制。为了解决这些问题，本研究旨在使用热水滴定技术配制柠檬草负载的SLN（LGSLN）。在Smix中,选择吐温80作为表面活性剂组分,而乙醇作为助表面活性剂。使用不同比例的Smix(1:1、1:2、1:3、2:1和3:1)来配制装载LG的SLN。结果表明，LGSLN配方（缩写为LGSLN1），含有10%w/w的脂质相(即，LG3.33%和SA6.67%），吐温80(20%w/w),乙醇（20％w/w）和蒸馏水（50％w/w），显示出合适的纳米尺寸（142.3±5.96nm），具有高ζ电位值（-29.12±1.7mV）和高包封率（77.02±8.12％）。在24小时的时间跨度内观察到LGSLN1的快速药物释放(71.65±5.33%)。稳态通量的最高值（Jss；0.6133±0.0361mg/cm2/h），LGSLN1还赋予了渗透系数（Kp;0.4573±0.0141（cm/h）×102）和增强率（Er;13.50）。根据体外研究结果，开发的SLN似乎是增强柠檬草油局部给药的潜在载体。观察到的结果还表明，对于广泛的临床适用性，可以进一步探索纳米脂质载体利用药学上可接受的成分局部施用柠檬草油的植物药用学前景。
■在线版本包含补充材料，可在10.1007/s13205-023-03726-5获得。
■在线版本包含补充材料，可在10.1007/s13205-023-03726-5获得。
